Rheumatoid arthritis is a leading autoimmune condition affecting roughly 700,000 to 1 million people in Japan (about 0.5–1% of the population). Women are affected about three times as often as men, and onset in the 30s to 50s accounts for two-thirds of cases — though elderly-onset rheumatoid arthritis (EORA) has been increasing, accumulating elderly long-term patients as the population ages.
RA is not an acute condition that ends with cure; diagnosis leads to lifelong pharmacological management and regular monitoring. The defining characteristic, from a clinic management perspective, is that the patient base once built keeps returning over years — making this an exceptionally recurring field.
1. Macro environment — alignment with T2T and continuity evaluation
The treatment paradigm of Treat to Target (T2T) has established itself as the standard internationally: set clear goals of remission or low disease activity early, and escalate treatment promptly if not achieved. That trend toward early, aggressive treatment has driven expanded use of biologics and JAK inhibitors, and the spread of joint ultrasound for early diagnosis.
The FY2026 revision weighted allocation toward personnel costs (increased base-up evaluation fees extended to all professions) and healthcare DX (abolishing the promotion readiness add-on and restructuring it into an electronic clinical information coordination readiness add-on).
Additionally, revising the outpatient data submission add-on toward evaluation based on continuing visits and management status makes the direction toward evaluating actual operation and outcomes and continuity clear — aligning well with rheumatology's long-term chronic follow-up.
From a cost containment perspective, pressure to promote biosimilar use has intensified further through the revision.
2. Characteristics of newly opened clinics
The typical new rheumatology clinic is opened by a board-certified rheumatologist who practiced rheumatology and connective tissue disease at a university or core hospital, declaring rheumatology, connective tissue disease internal medicine, and internal medicine and allergy together.
Making "rheumatology" and "connective tissue disease" explicit in the clinic name and foregrounding board certification on the website is common — an acquisition strategy responding to the tendency for patients to choose based on whether a specialist is present rather than on the specialty name.
On equipment, introducing joint ultrasound at opening to complete early diagnosis and treatment response assessment in-house is close to the current standard. Administering biologics by infusion in-house requires infusion space, nursing capability, and regimen management, with the facility standards for the outpatient chemotherapy add-on shaping the opening design. Where subcutaneous and self-injection instruction predominates, equipment investment is comparatively light, with revenue from injection procedure fees and home self-injection guidance fees.
On structure, because the clinic handles expensive drugs, the choice between in-house and external dispensing is a significant decision for cash flow, inventory risk, and drug price margin. In-house dispensing of expensive drugs carries heavy working capital burden and rejection risk, so a hybrid — external dispensing as the base with infusion products handled in-house — is also common.
Additionally, because first visits require testing, imaging, and differential diagnosis through to treatment initiation, building a reputation for early specialist differentiation is key to reaching break-even in the early period.
3. Revenue areas specific to rheumatology
Managing expensive drugs and continuing visits
The revenue core lies in managing biologics and JAK inhibitors and the continuing outpatient care that accompanies them. Monthly drug prices are extremely high, at roughly the following levels (published values as of the April 2025 revision; 30% coinsurance amounts in the right column).
| Drug class | Example | Monthly drug price | At 30% coinsurance |
|---|---|---|---|
| TNF inhibitor (subcutaneous) | Humira 40mg | ~¥93,728 | ~¥28,118 |
| IL-6 inhibitor (subcutaneous) | Actemra | ~¥65,216 | ~¥19,565 |
| T-cell selective (subcutaneous) | Orencia | ~¥114,188 | ~¥34,256 |
| JAK inhibitor (oral) | Olumiant 4mg | ~¥144,600 | ~¥43,380 |
| JAK inhibitor (oral) | Rinvoq 15mg | ~¥129,774 | ~¥38,932 |
These are heavy burdens for patients, but most are mitigated through the high-cost medical expense benefit system, and use continues within insured care.
For the clinic, the stable revenue source is not the drug itself but the repetition of management that makes continued safe use possible — regular blood testing, infection screening, response assessment, adverse event monitoring. Because switching agents occurs based on response and side effects, ongoing specialist management carries high value.
Infusion and injection management
Administering intravenous biologics such as infliximab, tocilizumab, and abatacept in-house qualifies for the outpatient chemotherapy add-on covering non-malignant conditions. For patients 15 and over, add-on 1 is cited at 450 points and add-on 2 at 370, with add-on 1 requiring dedicated full-time physicians, nurses, and pharmacists plus a regimen evaluation committee, and add-on 2 relaxed for existing clinics without physician staffing requirements.
Infusion carries high care density per session, stacking injection procedures, add-ons, and management fees on administration days — while long dosing intervals (weeks to months) make slot smoothing a challenge.
Joint ultrasound for early diagnosis and monitoring
Joint ultrasound uses power Doppler to visualize synovitis (active inflammation), capturing early arthritis invisible on radiographs and assessing the quality of remission (imaging remission) — making it the core tool for practicing T2T, now widespread in specialist clinics.
It is an examination that tests physician skill, and being able to diagnose early and demonstrate treatment response objectively connects directly to differentiation, patient conviction, and improved continuation rates.
Biosimilars and revision incentives
Amid cost containment, biosimilar use is strongly promoted as policy. Commentary on FY2026 organizes the biosimilar use structure add-on around requirements including usage counts over the preceding year, volume share targets by ingredient (50% or more for infliximab, adalimumab, and others), and, alongside in-clinic posting, mandatory website disclosure in principle.
Because rheumatology uses these ingredients heavily, biosimilar switching policy affects the business on three fronts: patient burden, add-on capture, and drug cost management.
Specialty boundaries and positioning
"Which specialty treats rheumatism?" is unclear to patients, creating a positioning opportunity. Connective tissue disease internal medicine is strong in systemic pharmacological management with biologics and JAK inhibitors, handling complications such as interstitial pneumonia, and managing comorbidities. Orthopedics is strong in surgery for joint deformity and arthroplasty, and in local and functional care through joint injection, orthotics, and rehabilitation.
Designing hospital and inter-clinic coordination — surgery to core hospitals, rehabilitation and orthotics to local partners — sustains a specialist clinic.
4. Self-pay services — structurally minimal
Self-pay in rheumatology is extremely limited, and that is best understood as a premise rather than a problem.
Standard RA treatment is pharmacotherapy anchored in methotrexate plus biologics or JAK inhibitors — all completed within insured care. The Japan Rheumatism Foundation's Q&A cites academic literature finding no benefit beyond placebo for supplements, and positions hot spring therapy as an adjunct — taking a clearly cautious stance toward uninsured and alternative therapies. The very notion of a specialist earning substantially from self-pay menus sits uneasily with academic values in this field.
Self-pay in practice centers on peripheral items: second opinions, uninsured testing, and document fees.
Management strategy should therefore not place self-pay at the center. Being chosen for the quality of insured care — early diagnosis, specialist pharmacological management, continuing follow-up — is the main path, with self-pay kept complementary and limited.
5. Management implications
Rheumatology practice is not a high-value episodic model but a recurring model: capture patients early through specialization, then manage them safely over the long term.
First, revenue comes not from the expensive drugs themselves but from the ongoing management that makes continued safe use possible. With ageing and rising EORA, the long-term patient pool is expected to keep expanding, and the length of each patient's lifetime treatment horizon raises lifetime value.
Second, early diagnosis and imaging remission assessment through joint ultrasound is the weapon for differentiation and continuation in the T2T era, with physician skill and equipment investment directly competitive.
Third, whether to handle infusion in-house or operate lean around subcutaneous and self-injection is the fork in opening design.
Fourth, biosimilar promotion gained further regulatory force in FY2026, so switching policy carries business impact across add-ons, drug costs, and patient burden.
Fifth, keep self-pay limited; being chosen for insured care quality and coordination is the established path.
6. How an AI EMR addresses these problems — feature by feature
In rheumatology, time-series data accumulates over years: disease activity scores, blood work, joint ultrasound findings, medication history. T2T is a strategy of continuously measuring progress against a target, and adverse event and infection monitoring for expensive drugs cannot be missed. Here is how Pottech's AI Karte supports that, feature by feature.
Feature 1: AI assistant — visualize disease activity score trajectories
Summarizes lab and score trends and personalizes patient-facing explanations.
T2T is a treatment strategy of continuously measuring progress against a target. Disease activity scores such as DAS28 and CDAI, CRP and ESR, joint ultrasound findings. Only when these can be followed longitudinally can you judge whether to escalate or maintain.
At the same time, being able to show patients treatment response objectively shapes continuation rates. For patients continuing expensive drugs long-term, seeing improvement in numbers is itself the motivation to continue. Both showing it on ultrasound and demonstrating it in scores differentiate this specialty.
Feature 2: Billing and claims — manage expensive drug and biosimilar add-on requirements
An automated calculation engine checks bundling conflicts, exclusions, and frequency limits, and determines eligibility automatically.
The biosimilar use structure add-on carries track record requirements — usage counts over the preceding year and volume share targets by ingredient (50% or more). Progress cannot be known without aggregating individual prescriptions. Mandatory website disclosure adds a further readiness management requirement.
The outpatient chemotherapy add-on also differs in facility standards between tiers 1 and 2, and infusion days stack injection procedures, add-ons, and management fees. Together with home self-injection guidance fees, in a specialty with this many billing elements, missed billing cuts directly into profit.
Feature 3: Charting and orders — structure routine monitoring documentation
AI generates SOAP notes from consultation audio, with template registration and recall, and set orders for tests and prescriptions.
Rheumatology outpatient care is dominated by return visits with highly standardized documentation patterns. Joint findings (tender and swollen joint counts), disease activity, adverse events, signs of infection — the same items confirmed and recorded each visit.
Recording these in structured form means more than time savings: it means preventing gaps in monitoring. Because biologics carry infection risk, missed regular blood work or tuberculosis screening bears directly on safety.
Feature 4: Patient PHR app integration ("Pote-kun") — prevent discontinuation of lifelong care
OCR capture of prescriptions with medication reminders, appointment booking, fee notifications, and LINE login with push notifications.
In a specialty premised on lifelong visits, continuation rate is the operating metric. For patients self-injecting, managing dosing timing is a daily burden, and reminders directly affect adherence.
Infusion products are administered every few weeks to months, and the longer the interval the more easily appointments are forgotten. Next-dose notifications serve both treatment quality and slot utilization.
Feature 5: Integrations and APIs — unify joint ultrasound images and lab data
An OAuth2 gateway, MCP server, and HAPI FHIR enable integration with external systems.
Joint ultrasound delivers value only through longitudinal comparison of the same joints. When images are disconnected from the chart, comparing against prior findings takes effort and cannot be shown to the patient.
With FY2026 shifting toward the electronic clinical information coordination readiness add-on and evaluation of actual My Number card and electronic prescription operation, building the data integration foundation matters for both add-on capture and operational efficiency.
Feature 6: Practice analytics — make continuing patient count the primary metric
Visit volume, revenue per patient, monthly trends, and patient attributes are aggregated and visualized automatically.
In a recurring model, net growth in continuing patients rather than new patient count reveals operating reality. Patients started on biologics and JAK inhibitors, continuation rates, switching incidence, biosimilar volume share.
Tracking these monthly enables both managing progress against add-on requirements and understanding growth in the patient pool.
Primary sources
- MHLW, "About the FY2026 fee schedule revision" https://www.mhlw.go.jp/stf/newpage_67729.html
- Layered Inc., "Impact of and response to the FY2026 fee revision" https://layered.inc/works/column/shinryo-hoshu-kaitei-2026/
- Medical Care Support, "Biosimilar use structure add-on (FY2026)" https://medicalcare-support.jp/articles/biosimilar-shiyou-taisei-kasan-2026
- MHLW biosimilar promotion site https://www.mhlw.go.jp/biosimilar
- Yakuyomi, "The outpatient chemotherapy add-on: eligible drugs and facility standards" https://yakuyomi.jp/career_skillup/skillup/02_185/
- Hosaka Clinic, "Drug costs for biologics and JAK inhibitors (April 2025 revision)" https://www.hosaka-clinic.com/price202204/
- Keio University Hospital KOMPAS, "Medical treatment of rheumatoid arthritis" https://kompas.hosp.keio.ac.jp/disease/000715/
- Japan College of Rheumatology, "What is a board-certified rheumatologist?" https://www.ryumachi-jp.com/general/jcr-board_certified_rheumatologist/
- Japan Rheumatism Foundation, "T2T in rheumatoid arthritis" https://www.rheuma-net.or.jp/rheuma/rheuma/t2t/
- Japan Rheumatism Foundation, "Rheumatism Q&A (supplements and alternative therapies)" https://www.rheuma-net.or.jp/rheuma/faq-list/general-medical/